CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Indevus Pharmaceuticals is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Indevus Pharmaceuticals
33 HAYDEN AVENUE
Phone: (617) 861-8444p:617 861-8444 LEXINGTON, MA  02421  United States Ticker: IDEVIDEV
This company was Merged or Acquired on 3/23/2009.
This company ceased filing statements with the SEC on 4/2/2009.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Indevus Pharmaceuticals, Inc. (Indevus) is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. The Company’s products include SANCTURA and SANCTURA XR for overactive bladder (OAB), which it co-promotes with its partner Allergan, Inc. (Allergan); VANTAS for advanced prostate cancer; SUPPRELIN LA for central precocious puberty (CPP), and DELATESTRYL for the treatment of hypogonadism. Its advanced compounds are VALSTAR for bladder cancer, NEBIDO for hypogonadism, PRO 2000 for the prevention of infection by human immunodeficiency virus (HIV) and other sexually transmitted pathogens, and the octreotide implant for acromegaly and carcinoid syndrome. In March 2009, Endo Pharmaceuticals Holdings Inc. completed the acquisition of Indevus.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 IRA CQ
Score		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating		 Morningstar
Rating
-Yes-------

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20089/30/2008YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Glenn L.Cooper 62 3/23/2009 5/1/1993
Chief Executive Officer, Director David P.Holveck 68 3/23/2009 2/23/2009
Chief Financial Officer, Executive Vice President, Treasurer Michael W.Rogers 55 2/1/1999 2/1/1999
5 additional Officers and Directors records available in full report.

Business Names
Business Name
CPEC LLC
Endo Pharmaceuticals Solutions Inc.
IDEV
5 additional Business Names available in full report.

General Information
Number of Employees: 246 (As of 9/30/2008)
Outstanding Shares: 78,187,924 (As of 12/31/2008)
Shareholders: 578
Stock Exchange: NASD
Federal Tax Id: 043047911
Fax Number: (302) 655-5049


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, October 24, 2019